All In Biotech

Drug Trial Radar · NCT07328022

Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis

Efficacy and Safety Study of the Etoricoxib/Betamethasone Combination Compared With Etoricoxib for the Treatment of Patients Diagnosed With an Acute Episode of Bursitis, Tendinitis, or Synovitis of the Shoulder, Elbow, Knee, or Ankle

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

89

Actual

Start

May 14, 2025

Primary completion

Aug 20, 2025

Study completion Nov 19, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III, multicenter, prospective, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib/betamethasone compared with etoricoxib alone in patients with an acute episode of bursitis, tendinitis, or synovitis affecting the shoulder, elbow, knee, or ankle.

Conditions

  • Bursitis
  • Tendinitis
  • Synovitis

Interventions

  • Fixed Dose Etoricoxib + BetamethasoneDrug

    One tablet of 90 mg / 0.25 mg a day, for 14 days

  • Monotherapy EtoricoxibDrug

    One tablet aog 90 mg a day, for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pain during active movement of the affected joint (VAS 100 mm) at Days 3, 7, 10, and 14 vs baseline, by treatment group.Time frame: Baseline and Days 3, 7, 10, and 14
  2. Number of participants with adverse events, and comparison of adverse event frequency and intensity, by treatment group.Time frame: Up to 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laboratorios Silanes, S.A. de C.V.

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.